{"id":941011,"date":"2026-03-02T09:07:48","date_gmt":"2026-03-02T14:07:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/"},"modified":"2026-03-02T09:07:48","modified_gmt":"2026-03-02T14:07:48","slug":"trevi-therapeutics-to-participate-in-upcoming-march-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/","title":{"rendered":"Trevi Therapeutics to Participate in Upcoming March Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., March  02, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mvebr7d1eML7ISTzM5TLSYLElAtSyRVg1dhcgzj3fpsA7vRu2sBcTpi0BDiDBP_hfQFu_LLmgK0wmQ2g4oOlgavLJuypKFsQB5MNFEGFHLU_2DHNtXqp5wepbvyTBuBs\" rel=\"nofollow\" target=\"_blank\">Trevi Therapeutics, Inc.<\/a> (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March.<\/p>\n<p>\n        <strong><br \/>\n          <u>Leerink Partners 2026 Global Healthcare Conference<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>March 8 \u2013 11, 2026, Miami, Florida<br \/><strong>Fireside Chat:<\/strong> March 11, 8:40 a.m. ET<br \/><strong>Trevi Representatives:<\/strong> Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4kDUeeBJkYTo9qiP878RNaA6KTGj_Qrqf_mg8s-AHsOE6IQaFTzu8afb4At399aZDukx3C_y5ppO96dJWxob_LbBbGUYE1fMkEol_fhU_Rf9DN0QClJJzV8S0LwcymfEunaZqjbOnm_o3fv99dbdLMFwoNjKnCDaiq16fTaMW51BVpXcTk8GvmSgBPWNSjikx7JJ8QDcMiwQIrpmnJlrt13wc2XNEwLiHlfpZolHzmM=\" rel=\"nofollow\" target=\"_blank\">Register here to watch the live webcast.<\/a><\/p>\n<p>\n        <strong><br \/>\n          <u>Access USA, Rare Disease Summit 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>March 17 \u2013 19, 2026, Philadelphia, Pennsylvania <br \/><strong>Panel:<\/strong> Architecting Success \u2013 Building a Foundation for Rare Disease Launch Excellence<br \/><strong>Session: <\/strong>March 18, 9:00 \u2013 9:45 a.m. ET <br \/><strong>Trevi Representative: <\/strong>Farrell Simon, Pharm.D., CCO<\/p>\n<p>\n        <strong>About Trevi Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.<\/p>\n<p>Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients&#8217; quality of life.<\/p>\n<p>RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.<\/p>\n<p>For more information, visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s8VzOI60P7J7kIMeP7OYZIKUEmGPJhSHEZnxwCH2GI0khrMvYERaMa9lf_TchVzjuxZKhXJgqcA20zlMm9QaEBcduYLyOYESfgX0Cb5UafWtO1Vy5zq4S0GA7fMclFOf\" rel=\"nofollow\" target=\"_blank\"><u>www.TreviTherapeutics.com<\/u><\/a>\u202fand follow Trevi on\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=owJUqvp_-5dW4-_yd7oVjLJhlCrDiXYTiUBw2yNs8vYsux1WciA_m3Y4VwgzH-dWgstuo-0tA5AudtglthJ4nA==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>\u202f(formerly Twitter) and\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hCJMuyngN9s9YqGGuqce2pVY7zCp3PMqhERuvLKNcBpkuzBn8NTWldSiYqyxbHsDK-DSiYDvikeJSrch6wOcVlu53cxaZ1rZ9_WXjwxC9nxJNKX8PveFRhBv9wpfXH0M\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\u202f<br \/>Jonathan Carlson<br \/>Trevi Therapeutics, Inc.<br \/>(203) 654 3286<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZRgVW3OtD6QKPZ6JdBllhMPoAHjIgH04To3KiMFWm_Mi3ffaGxW1gG9mCpE1okri0J1ZngAdbCozx2GBw_QFQA==\" rel=\"nofollow\" target=\"_blank\">IR@trevitx.com<\/a><\/u><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Rosalia Scampoli<br \/>914-815-1465<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PIzHgk1MgGBGn4NX30eIogst9kD9g8RKq_9__JIPUpXao4A3Uo0UXcyfwrMgOJS-_mgVtiQtY1XUcEbKWfYhywJzZ8r-fO-YOe-Hrl9VGyP5zQvqJg2v8zO8YL9v99Rs\" rel=\"nofollow\" target=\"_blank\">rscampoli@marketcompr.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBkZjQzZTItODBmYy00Njk1LWE1ZGMtMDRlN2Q3NGU1MGUyLTExMzY2ODctMjAyNi0wMy0wMi1lbg==\/tiny\/Trevi-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare Conference March 8 \u2013 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister here to watch the live webcast. Access USA, Rare Disease Summit 2026 March 17 \u2013 19, 2026, Philadelphia, Pennsylvania Panel: Architecting Success \u2013 Building a Foundation for Rare Disease Launch ExcellenceSession: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Participate in Upcoming March Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941011","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare Conference March 8 \u2013 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister here to watch the live webcast. Access USA, Rare Disease Summit 2026 March 17 \u2013 19, 2026, Philadelphia, Pennsylvania Panel: Architecting Success \u2013 Building a Foundation for Rare Disease Launch ExcellenceSession: &hellip; Continue reading &quot;Trevi Therapeutics to Participate in Upcoming March Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T14:07:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Upcoming March Conferences\",\"datePublished\":\"2026-03-02T14:07:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/\"},\"wordCount\":506,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/\",\"name\":\"Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\",\"datePublished\":\"2026-03-02T14:07:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Upcoming March Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk","og_description":"NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare Conference March 8 \u2013 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister here to watch the live webcast. Access USA, Rare Disease Summit 2026 March 17 \u2013 19, 2026, Philadelphia, Pennsylvania Panel: Architecting Success \u2013 Building a Foundation for Rare Disease Launch ExcellenceSession: &hellip; Continue reading \"Trevi Therapeutics to Participate in Upcoming March Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T14:07:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Upcoming March Conferences","datePublished":"2026-03-02T14:07:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/"},"wordCount":506,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/","name":"Trevi Therapeutics to Participate in Upcoming March Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=","datePublished":"2026-03-02T14:07:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Mjk3NCM3NDU5MzU0IzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Upcoming March Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941011"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941011\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}